Wedbush Has Strong Forecast for BCRX FY2025 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Analysts at Wedbush upped their FY2025 earnings per share estimates for BioCryst Pharmaceuticals in a report released on Tuesday, July 15th. Wedbush analyst L. Chico now expects that the biotechnology company will earn $0.13 per share for the year, up from their prior forecast of $0.11. Wedbush has a “Outperform” rating and a $18.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals’ FY2028 earnings at $1.03 EPS.

BCRX has been the topic of a number of other research reports. Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 28th. Bank of America upped their price target on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, July 1st. JPMorgan Chase & Co. upped their price target on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an “overweight” rating in a research report on Tuesday, May 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $17.00 price target on shares of BioCryst Pharmaceuticals in a research report on Wednesday, June 25th. Finally, Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They set an “overweight” rating and a $20.00 price objective on the stock. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.70.

BioCryst Pharmaceuticals Trading Down 1.5%

Shares of BCRX opened at $8.59 on Wednesday. The stock has a market capitalization of $1.80 billion, a P/E ratio of -33.04, a price-to-earnings-growth ratio of 2.46 and a beta of 1.04. The firm’s fifty day simple moving average is $9.97 and its two-hundred day simple moving average is $8.66. BioCryst Pharmaceuticals has a 12 month low of $6.02 and a 12 month high of $11.31.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Headlands Technologies LLC bought a new position in BioCryst Pharmaceuticals in the 1st quarter valued at about $32,000. GF Fund Management CO. LTD. bought a new position in BioCryst Pharmaceuticals in the 4th quarter valued at about $33,000. GAMMA Investing LLC lifted its position in BioCryst Pharmaceuticals by 1,161.8% in the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 5,449 shares in the last quarter. New Age Alpha Advisors LLC bought a new position in BioCryst Pharmaceuticals in the 1st quarter valued at about $62,000. Finally, Family Legacy Financial Solutions LLC bought a new position in BioCryst Pharmaceuticals in the 2nd quarter valued at about $72,000. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.